Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Files An 8-K Results of Operations and Financial Condition
Item2.02 Result of Operations and Financial Condition.
On May12, 2017, Eiger BioPharmaceuticals, Inc. issued a press
release announcing certain financial results for the three months
ended March31, 2017. A copy of this press release is furnished to
Item2.02 as Exhibit 99.1 hereto.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
| 99.1 | Press Release, dated May 12, 2017. |
The information in this report, including the exhibit hereto,
shall not be deemed to be filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that Section11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained
herein and in the accompanying exhibit shall not be incorporated
by reference into any filing with the U.S. Securities and
Exchange Commission made by Eiger BioPharmaceuticals, Inc.,
whether made before or after the date hereof, regardless of any
general incorporation language in such filing.
About Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Recent Trading Information
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) closed its last trading session down -0.50 at 7.05 with 21,572 shares trading hands.
